References
1. Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A, Jedrzejczak-Czechowicz M, Doan S, Marmouz F, Demoly P, Delgado L. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy 2012;67:1327-1337.
2. Sheldrick JH, Wilson AD, Vernon SA, Sheldrick CM. Management of ophthalmic dis-ease in general practice. Br J Gen Pract 1993;43(376):459-62.
3. Manners T. Managing eye conditions in general practice. BMJ 1997;315: 816-817
4. Bielory L, Skoner DP, Blaiss MS, Leatherman B, Dykewicz MS, Smith N, Ortiz G, Had-ley JA, Walstein N, Craig TJ, Allen-Ramey F. Ocular and nasal allergy symptom burden in America: the Allergies, Immunotherapy, and Rhinoconjunctivitis (AIRS) surveys. Allergy Asthma Proc 2014 May-Jun;35(3):211-8.
5. Bousquet J, Khaltaev N, Cruz AA, et al: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update [in collaboration with the World Health Organization, GA(2)LEN and Al-lerGen]. Allergy 2008; 63(86):8-160.
6. Eriksson NE, Holmen A: Skin prick tests with standardized extracts of inhalant aller-gens in 7,099 adult patients with asthma or rhinitis: cross-sensitizations and relationships to age, sex, month of birth and year of testing. J Investig Allergol Clin Immunol 1996;6:36-46.
7. Bousquet PJ, Chinn S, Janson C, Kogevinas M, Burney P, Jarvis D: Geographical varia-tion in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I. Allergy 2007;62: 301-309.
8. Pfaar O, Karatzas K, Bastl K, et al. Pollen season is reflected on symptom load for grass and birch pollen-induced allergic rhinitis in different geographic areas—An EAACI Task Force Report. Allergy 2020;75:1099-1106.
9. Caillaud D, Martin S, Segala C, Besancenot J-P, Clot B, Thibaudon M. Effects of air-borne birch pollen levels on clinical symptoms of seasonal allergic rhinoconjunctivitis. Int Arch Allergy Immunol 2014;163:43-50.
10. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990 jan;108(1):84‑8.
11. Fauquert JL, Jedrzejczak-Czechowicz M, Rondon C, Calder V, Silva D, Kvenshagen BK, et al. Conjunctival allergen provocation test: guidelines for daily practice. Allergy 2017;72(1):43-54.
12. Horak F, Berger UE, Menapace R, Toth J, Stübner PU, Marks B. Dose-dependent pro-tection by azelastine eye drops against pollen-induced allergic conjunctivitis. A double-blind, placebo-controlled study. Arzneimittelforschung 1998;48:379-384.
13. Horak F, Stübner P, Zieglmayer R, Kawina A, Moser M, Lanz R. Onset and duration of action of ketotifen 0.025% and emedastine 0.05% in seasonal allergic conjunctivitis: efficacy after repeated pollen challenges in the Vienna challenge chamber. Clin Drug Investig 2003;23:329-323.
14. Pfaar O, Calderon MA, Andrews CP, Angjeli E, Bergmann KC, Bønløkke JH, et al. Al-lergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper. Allergy 2017;72(7):1035-1042.
15. Rösner-Friese K, Kaul S, Vieths S, Pfaar O. Environmental exposure chambers in aller-gen immunotherapy trials: Current status and clinical validation needs. J Allergy Clin Immu-nol 2015;135:636‑643.
16. Khayath N, Doyen V, Gherasim A, Radu C, Choual I, Beck N, Jacob A, Schoettel F, Ve-cellio L, Domis N, de Blay F. Validation of Strasbourg environmental exposure chamber (EEC) ALYATEC in mite allergic subjects with asthma. J Asthma 2020 Feb;57(2):140-148.
17. Gherasim A, Jacob A, Schoettel F, Domis N, de Blay F. Efficacy of air cleaners in asthmatics allergic to cat in ALYATEC® environmental exposure chamber. Clin Exp Aller-gy.2020 Feb;50(2):160-169.
18. Baudoin C. Formes frontières de l’allergie. [Neighboring forms of allergy]. J Fr. Oph-talmol, 2007;30(3):306-313.
19. Bertel F, Mortemousque B, Sicard H, André C. Test de provocation conjonctivale au Dermatophagoïdes pteronyssinus dans le diagnostic des conjonctivites allergiques aux aca-riens domestiques [Conjunctival provocation test with Dermatophagoides pteronyssinus in the diagnosis of allergic conjunctivitis from house mites]. J Fr Ophtalmol. 2001 Jun;24(6):581-9.
20. Buters J. T.M, Thibaudon M, Smith M, Kennedy R, Rantio-Lehtimäki A, Albertini R, Reese G, Weber B, Galan C, Brandao R, Antunes CM, Jäger S, Berger U, Celenk S, Grewling Ł, Jackowiak B, Sauliene I, Weichenmeier I, Pusch G, Sarioglu H, Ueffing M, Behrendt H, Prank M, Sofiev M, Cecchi L. The HIALINE working group. Release of Bet v 1 from birch pol-len from 5 European countries. Results from the HIALINE study. Atmospheric Environment 2012, 55:496-505.
21. Prince A, Norris MR, Bielory L. Seasonal ocular allergy and pollen counts. Curr Opin Allergy Clin Immunol 2018 Oct;18(5):387-392.
22. Jacobs RL, Ramirez DA, Rather CG, Andrews CP, Jupiter DC, Trujillo F, et al. Redness response phenotypes of allergic conjunctivitis in an allergen challenge chamber. Ann Allergy Asthma Immunol 2017; 118(1):86-93.
23. Patel D, Garadi R, Brubaker M, Conroy JP, Kaji Y, Crenshaw K, et al. Onset and dura-tion of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc 2007; 28:592-9.
24. Ellis AK, Ratz JD, Day AG, Day JH. Factors that affect the allergic rhinitis response to ragweed allergen exposure. Ann Allergy Asthma Immunol 2010; 104:293-298.
25. Day JH, Brisoce MP. Environmental exposure unit: a system to test anti-allergic treatment. Ann Allergy Asthma Immunol 1999; 83:83-93.
26. Zieglmayer P. Are results of environmental exposure units transferable to real-life exposure? Curr Opin Allergy Clin Immunol 2013, 13:244–2480.028.